FilingReader Intelligence
Southern Shuanglin Bio-Pharmacy profit falls 28% amid expansion
August 22, 2025 at 05:49 AM UTC•By FilingReader AI
Southern Shuanglin Bio-Pharmacy's net profit fell 27.89% to 235.8 million yuan in the first half of 2025, primarily due to reduced product supply during capacity expansion that increased total annual capacity to over 3,000 tons.
China National Biotec Group became the new controlling shareholder. The company also terminated an overseas trade agreement for intravenous immunoglobulin in Brazil due to market changes and regulatory adjustments.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
2025 semi-annual reportAugust 21, 2025 at 08:00 AM UTC
Summary table of semi-annual non-operating fund occupation and other related party fund transactionsAugust 21, 2025 at 08:00 AM UTC
2025 semi-annual report summaryAugust 21, 2025 at 08:00 AM UTC
Announcement of board resolutions for the semi-annual reportAugust 21, 2025 at 08:00 AM UTC
Special report on the deposit and use of raised funds for the first half of 2025August 21, 2025 at 08:00 AM UTC
Announcement on the reappointment of the auditing firm for the 2025 financial yearAugust 21, 2025 at 08:00 AM UTC
Notice of the second extraordinary general meeting of shareholders in 2025August 21, 2025 at 08:00 AM UTC
Announcement regarding the progress of significant contracts for export trade registration in compliance with overseas market regulationsAugust 21, 2025 at 08:00 AM UTC
News Alerts
Get instant email alerts when Southern Shuanglin Bio-Pharmacy publishes news
Free account required • Unsubscribe anytime